ABN401 clinical trials phase 2- first patient enrolled
2022
05
Contract signed with MediRama for ABN401 Global Clinical Trials Phase 2
04
Capital contribution to ABTS (ABION Biotechnology and Science), ABION’s US subsidiary
2021
09
Listed on KOSDAQ
03
Joined by a strategic investor “Labgenomics” for the development of anti-cancer drug
01
ABN401 IND approved for global clinical development stage I/2 by U.S. FDA
2020
06
Research service contract signed with ADD for Pre-clinical Safety Assessment of dual gene-inserted vaccine
04
Reseach service contract signed with ADD for the production of non-clinical study drug substance of gene vaccine and siRNA
04
ABN401 Selected for Cutting-edge medical technology development project by the Korean Ministry of Health and Welfare
2019
11
Awarded for best IP R&D company by theKorean Ministry of Trade, Industry and Energy
09
ABION Signs Contract manufacturing agreement of ABN101 with Samsung Biologics
07
License-out of anti-c-MET agonist antibody technology
07
ABION Australia Pty Ltd founded as a Subsidiary
07
ABN401 IND approved for global clinical development stage I/2
2018
12
Research service contract with ADD for Target gene expression improvement and delivery efficacy research
11
License-in of SEB vaccine development technology
11
License-out of human interferon-beta variant conjugated immunocytokine (Her2)
04
ABN701 Selected for infectious disease biorisk technology development project by the Korean Ministry of Health and Welfare (Vaccine Development)
04
ABN401 Selected for a cutting-edge medical technology development project by the Korean Ministry of Health and Welfare
2017
12
License-out of composition for treatment of HPV related cancers
06
ABN401 Selected for Innovative Technology Development Project of MSS(Ministry of SMEs and Startups)
03
ABN101 Selected for Successful production of its variant for quality analysis and pre-safety profile, Leading to Next Generation of Interferon-β Agent at Osong Medical Innovation Complex
02
ABN201 Selected for Commercialization Plan Using Analysis Technology in Immune Disease of MSIT(Ministry of science, ICT and Future Planning)
2016
08
ABN401 Selected for a Korea Drug Development Fund research project
